Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | STAT1 | P42224 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | PHGDH | O43175 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.57 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339738 | 0.84 | KDM4E (0.67) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL1787240 | 0.84 | MAPT (1.00) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL7036878 | 0.81 | ALDH1A1 (0.58) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL2557746 | 0.80 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL20718445 | 0.80 | ALDH1A1 (0.63) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL19594975 | 0.79 | ALDH1A1 (0.56) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL396870 | 0.79 | ALDH1A1 (0.80) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL27702445 | 0.79 | HSPD1 (0.49) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL5655892 | 0.79 | GSK3B (0.64) | KDM4ERAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL2558084 | 0.79 | KDM4E (0.73) | KDM4ERAB9ANPC1MAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003081209-A2 | IDENTIFICATION OF LIGANDS FOR A RECEPTOR FAMILY AND RELATED METHODS | TRIAD THERAPEUTICS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030180797-A1 | Identification of ligands for a receptor family and related methods | TRIAD THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030104473-A1 | Common ligand mimics: benzimidazoles | TRIAD THERAPEUTICS, INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | KDM4E 2591/4885RAB9A 1475/4885NPC1 2897/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | KDM4E 1039/4885RAB9A 4583/4885NPC1 1437/4885 |
| US-20030104473-A1 | Common ligand mimics: benzimidazoles | BID, LIFR, FGFR3 | KDM4E 2634/4885RAB9A 4667/4885NPC1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.